- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior
- World's Largest Share Issue Priced at Deep Discount
- Obama says Boosting US Jobs is Top Priority
- GM to Cut up to 9,500 Jobs in Europe
- Playboy to Outsource Most Magazine Operations: Report
- Why the Dollar Will Likely Stay Weak for Some Time
- Appeals Court Denies Microsoft's Alcatel Petition
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Why Amazon Rules Retail
- Wave of Debt Payments Facing US Government
- The Social Media Gaming Threat
- China Eastern to Complete Shanghai Air Buy by End '09
- Paul: Audit the Fed
- JAL Slides to Record Low on Bankruptcy Jitters
- Gold Will Collapse Like Oil Did in 2008: Charts
- Prepare For Large Decline In Stocks, Next Year?
- Lyondell Urged to Consider Reliance Takeover Offer
Text Size 
Bowing to pressure from an Icos [ICOS
Loading...
()
] shareholder, Eli Lilly [LLY
Loading...
()
] said it has increased its offer for the biotechnology company to $2.3 billion from an earlier bid of $2.1 billion.
The revised price of $34 a share follows objections from HealthCor, a big Icos shareholder, to the earlier $32-a-share offer. HealthCor argued that Icos was worth more than $40 a share.
Lilly, which agreed in October to acquire Icos to gain full ownership of the erectile dysfunction drug Cialis, said its latest offer is its "best and final offer."
"We are confident that Icos shareholders will recognize the substantial value and the certainty that Lilly is offering," Sidney Taurel, Lilly's chief executive officer, said in a statement.
Indianapolis-based Lilly, which currently markets Cialis with Icos through a joint venture, said the boards of both companies have unanimously approved the new offer.
Lilly is eager to take advantage of a revival in the erectile dysfunction market, which was hurt last year by concerns that drugs to treat the condition, including Pfizer [PFE
Loading...
()
] Viagra, could cause blindness.
News of the increased Icos bid comes a day after a report on the New York Times' Web site that Eli Lilly downplayed risks associated with Zyprexa, a drug it makes for the treatment of schizophrenia. Zyprexa is Eli Lilly's best-selling product, the Times said.
Print
Email
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- CNBC’s Phil LeBeau took a test drive of GM’s flagship electric car. Here’s what he thought of the Volt.
- The energy company Power Efficiency is building tools that regulate the power electric motors use.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes